Pharmamarketeer

Sanofi’s Dupixent extended in Europe to cover adolescents in atopic dermatits

Sanofi has announced that European Commission (EC) has chosen to extend the marketing approval of its interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) to cover the treatment of adolescent patients aged between 12 and 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

read more

Advertentie(s)
Geen nieuws missen?
Volg de duizenden farma professionals die Pharmamarkteer.nl via e-mail lezen

Uw inschrijving is gelukt.
Bedankt!
Naar Pharmamarkteer.nl